Body Weight, the Tumor Necrosis Factor System, and Leptin Production during Treatment with Mirtazapine or Venlafaxine
The DOI matches its Crossref record.
Abstract
Weight gain is a frequent and important side effect of psychopharmacotherapy. Recent studies suggest that the fat-cell-derived hormone leptin and the tumor necrosis factor-alpha (TNF-alpha) cytokine system are pathophysiologically involved. No information is available concerning the influence of the antidepressants mirtazapine and venlafaxine on these immunoendocrine variables. An open-labeled study was performed in 20 patients suffering from major depression treated with either mirtazapine (N = 11) or venlafaxine (N = 9). During 4 weeks, the patients' weight, body mass index (BMI), and plasma levels of leptin, TNF-alpha, sTNF-R p55, and sTNF-R p75 were assessed. Mirtazapine induced a significant increase in weight (mean weight gain: 2.4 kg) that was evident after the first week of treatment. In parallel, the plasma levels of TNF-alpha and both soluble TNF receptors increased. In addition, a slight rise in leptin levels, which occurred slowly and was significant only at the end of the 4 th week of treatment, was observed. Weight decreased slightly but significantly in patients treated with venlafaxine (mean weight loss: 0.4 kg), whereas plasma levels of leptin, TNF-alpha, or soluble TNF receptors did not change significantly. The present results further support the notion that the activation of the TNF-alpha cytokine system is an early, sensitive, and specific marker of weight gain induced by psychotropic agents. In contrast, the effects of such drugs on leptin production seem to be less sensitive with respect to weight gain and more variable.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Whereas, mirtazapine induced a significant increase in the plasma levels of TNF-α and both soluble TNF receptors, venlafaxine did not alter plasma levels of TNF-α, or soluble TNF receptors significantly (201).”
From Cytokine Research in Depression: Principles, Challenges, and Open Questions (2019) · cites this paper as [201]
Citations
Cites
Still being checked.
Cited by
Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review
Potvin, S., Stip, E., Sepehry, A. A., Gendron, A., Bah, R., & Kouassi, E. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.024 · Cited by 858
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Are Mood Disorders and Obesity Related? A Review for the Mental Health Professional
McElroy, S. L., Kotwal, R., Malhotra, S., Nelson, E. B., Keck, P. E., & Nemeroff, C. B. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0507 · Cited by 652
Obesity and the skin: Skin physiology and skin manifestations of obesity
Yosipovitch, G., DeVore, A., & Dawn, A. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.12.004 · Cited by 524
Leptin: A potential novel antidepressant
Lu, X.-Y., Kim, C. S., Frazer, A., & Zhang, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508901103 · Cited by 446
Zimmermann, U., Kraus, T., Himmerich, H., Schuld, A., & Pollmächer, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00018-9 · Cited by 347
Self-citationMetabolic disturbances connecting obesity and depression
Hryhorczuk, C., Sharma, S., & Fulton, S. E. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00177 · Cited by 322
Cytokine Research in Depression: Principles, Challenges, and Open Questions
Himmerich, H., Patsalos, O., Lichtblau, N., Ibrahim, M. A. A., & Dalton, B. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00030 · Cited by 313
Effect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233
Ma, K., Zhang, H., & Baloch, Z. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050733 · Cited by 205
Th2 Cytokine Response in Major Depressive Disorder Patients before Treatment
Pavón, L., Sandoval-López, G., Eugenia Hernández, M., Loría, F., Estrada, I., Pérez, M., Moreno, J., Ávila, U., Leff, P., Antón, B., et al. (2006) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.08.014 · Cited by 187
Depression, comorbidities and the TNF-α system
Himmerich, H., Fulda, S., Linseisen, J., Seiler, H., Wolfram, G., Himmerich, S., Gedrich, K., Kloiber, S., Lucae, S., Ising, M., et al. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.03.013 · Cited by 181
Self-citationObesity, adipokines and neuroinflammation
Aguilar-Valles, A., Inoue, W., Rummel, C., & Luheshi, G. N. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.12.023 · Cited by 168
Schmid, D. A., Wichniak, A., Uhr, M., Ising, M., Brunner, H., Held, K., Weikel, J. C., Sonntag, A., & Steiger, A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300923 · Cited by 165
“Leptin morning levels were shown to increase during antidepressive treatment with mirtazapine (Kraus et al, 2002).”
BackgroundHope, S., Dieset, I., Agartz, I., Steen, N. E., Ueland, T., Melle, I., Aukrust, P., & Andreassen, O. A. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.08.003 · Cited by 164
Mirtazapine: A Review of its Use in Major Depression and Other Psychiatric Disorders
Croom, K. F., Perry, C. M., & Plosker, G. L. (2009) · CNS Drugs · doi:10.2165/00023210-200923050-00006 · Cited by 158
Cytokines as biomarkers in depressive disorder: current standing and prospects
Lichtblau, N., Schmidt, F. M., Schumann, R., Kirkby, K. C., & Himmerich, H. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.813442 · Cited by 155
Kluge, M., Schuld, A., Schacht, A., Himmerich, H., Dalal, M. A., Wehmeier, P. M., Hinze-Selch, D., Kraus, T., Dittmann, R. W., & Pollmächer, T. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.08.016 · Cited by 146
Self-citationBortolato, B., F. Carvalho, A., K. Soczynska, J., I. Perini, G., & S. McIntyre, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630171433 · Cited by 142
Adipokines as emerging depression biomarkers: A systematic review and meta-analysis
Carvalho, A. F., Rocha, D. Q. C., McIntyre, R. S., Mesquita, L. M., Köhler, C. A., Hyphantis, T. N., Sales, P. M. G., Machado-Vieira, R., & Berk, M. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.08.002 · Cited by 138
Weight gain and metabolic changes during treatment with antipsychotics and antidepressants
Himmerich, H., Minkwitz, J., & Kirkby, K. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150623092031 · Cited by 122
Phase II Trial of Mirtazapine for Cancer-Related Cachexia and Anorexia
Riechelmann, R. P., Burman, D., Tannock, I. F., Rodin, G., & Zimmermann, C. (2010) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909109345685 · Cited by 122
The TNF-α System: Functional Aspects in Depression, Narcolepsy and Psychopharmacology
Berthold-Losleben, M., & Himmerich, H. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777238 · Cited by 119
“All drugs investigated so far that induce weight gain - clozapine, olanzapine, amitriptyline and mirtazapine – also clearly activate the TNF- system [36, 44, 75, 85].”
BackgroundSuccessful Antidepressant Therapy Restores the Disturbed Interplay Between TNF-α System and HPA Axis
Himmerich, H., Binder, E. B., Kunzel, H. E., Schuld, A., Lucae, S., Uhr, M., Pollmächer, T., Holsboer, F., & Ising, M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.075 · Cited by 134
Self-citationDepression: Biological markers and treatment
Nedic Erjavec, G., Sagud, M., Nikolac Perkovic, M., Svob Strac, D., Konjevod, M., Tudor, L., Uzun, S., & Pivac, N. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110139 · Cited by 119
Hinze‐Selch, D., Däubener, W., Eggert, L., Erdag, S., Stoltenberg, R. L., & Wilms, S. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm010 · Cited by 117
Self-citationImpact of antidepressants on cytokine production of depressed patients in Vitro
Munzer, A., Sack, U., Mergl, R., Schönherr, J., Petersein, C., Bartsch, S., Kirkby, K., Bauer, K., & Himmerich, H. (2013) · Toxins · doi:10.3390/toxins5112227 · Cited by 114
“been reported to increase the plasma concentration of TNF-α and its soluble receptors (TNF-R) p55 and p75 in depressed patients [49].”
BackgroundMartino, M., Rocchi, G., Escelsior, A., & Fornaro, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604542 · Cited by 111
Allard, P., Gram, L., Timdahl, K., Behnke, K., Hanson, M., & Søgaard, J. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1190 · Cited by 105
Yang, K., Xie, G., Zhang, Z., Wang, C., Li, W., Zhou, W., & Tang, Y. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601057759 · Cited by 101
Medications that cause weight gain and alternatives in Canada: a narrative review
Wharton, S., Raiber, L., Serodio, K., Lee, J., & Christensen, R. A. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s171365 · Cited by 100
The impact of leptin on perinatal development and psychopathology
Valleau, J. C., & Sullivan, E. L. (2014) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2014.05.001 · Cited by 102
Eşel, E., Özsoy, S., Tutuş, A., Sofuoǧlu, S., Kartalcı, Ş., Bayram, F., Kokbudak, Z., & Kula, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.01.009 · Cited by 98
Narita, K., Murata, T., Takahashi, T., Kosaka, H., Omata, N., & Wada, Y. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.030 · Cited by 88
Serum Ghrelin and Leptin Levels in Patients with Depression and the Effects of Treatment
Ozsoy, S., Besirli, A., Abdulrezzak, U., & Basturk, M. (2014) · Psychiatry Investigation · doi:10.4306/pi.2014.11.2.167 · Cited by 79
De Berardis, D., Conti, C. M. V., Serroni, N., Moschetta, F. S., Olivieri, L., Carano, A., Salerno, R. M., Cavuto, M., Farina, B., Alessandrini, M., et al. (2010) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201002300204 · Cited by 77
Ruetsch, O., Viala, A., Bardou, H., Martin, P., & Vacheron, M. N. (2005) · L Encéphale · doi:10.1016/s0013-7006(05)82412-1 · Cited by 106
Schmidt, F. M., Schröder, T., Kirkby, K. C., Sander, C., Suslow, T., Holdt, L. M., Teupser, D., Hegerl, U., & Himmerich, H. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.02.052 · Cited by 74
Gomes‐da‐Costa, S., Marx, W., Corponi, F., Anmella, G., Murru, A., Pons-Cabrera, M. T., Giménez‐Palomo, A., Gutiérrez-Arango, F., Llach, C.-D., Fico, G., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.011 · Cited by 81
de Oliveira, R. A., Cunha, G. M. A., Borges, K. D. M., de Bruin, G. S., Filho, E. A. S., Viana, G. S. D. B., & de Bruin, V. M. S. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.09.001 · Cited by 75
Li, Z., Qi, D., Chen, J., Zhang, C., Yi, Z., Yuan, C., Wang, Z., Hong, W., Yu, S., Cui, D., et al. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.05.005 · Cited by 69
Kast, R. E. (2003) · General Hospital Psychiatry · doi:10.1016/s0163-8343(03)00093-8 · Cited by 62
Kurt, E., Güler, Ö., Serteser, M., Cansel, N., Özbulut, Ö., Altınbaş, K., Alataş, G., SAVAS, H. A., & Geçici, Ö. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.08.018 · Cited by 62
Himmerich, H., Koethe, D., Schuld, A., Yassouridis, A., & Pollm�cher, T. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2038-9 · Cited by 60
“All drugs investigated so far that induce weight gain—clozapine, olanzapine, amitriptyline and mirtazapine —also clearly activate the TNF-α system (Hinze-Selch et al. 2000; Kraus et al. 2002; Pollmächer et al. 1996; Schuld et al. 2000).”
BackgroundSelf-citationHimmerich, H. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.16.1739 · Cited by 57
Guo, M., & Lu, X.-Y. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.126 · Cited by 55
Kauffman, R. P., Castracane, V. D., White, D. L., Baldock, S. D., & Owens, R. (2005) · Gynecological Endocrinology · doi:10.1080/09513590500216800 · Cited by 53
Mirtazapine Provokes Periodic Leg Movements during Sleep in Young Healthy Men
Fulda, S., Kloiber, S. M., Dose, T., Lucae, S., Holsboer, F., Schaaf, L., & Hennings, J. M. (2013) · SLEEP · doi:10.5665/sleep.2622 · Cited by 49
Mirtazapine Inhibits Tumor Growth via Immune Response and Serotonergic System
Fang, C., Chen, H., Chiang, I., Chen, C.-C., Liao, J.-F., Su, T.-P., Chieh-Yin, T., Uchitomi, Y., & Hwang, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038886 · Cited by 51
Medical management of obesity associated with mental disorders.
Malhotra, S., & McElroy, S. L. (2002) · PubMed · Cited by 50
Megestrol Acetate and Mirtazapine for the Treatment of Unplanned Weight Loss in the Elderly
Fox, C. B., Treadway, A. K., Blaszczyk, A. T., & Sleeper, R. B. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.4.383 · Cited by 43
Early prediction of changes in weight during six weeks of treatment with antidepressants
Himmerich, H., Schuld, A., Haack, M., Kaufmann, C., & Pollmächer, T. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.02.002 · Cited by 42
Self-citationImpact of lithium alone and in combination with antidepressants on cytokine production in vitro
Petersein, C., Sack, U., Mergl, R., Schönherr, J., Schmidt, F. M., Lichtblau, N., Kirkby, K. C., Bauer, K., & Himmerich, H. (2015) · Journal of Neural Transmission · doi:10.1007/s00702-014-1328-6 · Cited by 40
Involvement of genetic factors in bipolar disorders: current status.
Weschenfelder, J., Sander, C., Kluge, M., Kirkby, K. C., & Himmerich, H. (2012) · PubMed · Cited by 43
Eller, T., Vasar, V, Shlik, J., & Maron, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108091077 · Cited by 40
Changes in the Hypothalamic-Pituitary-Adrenal Axis and Leptin Levels during Antidepressant Treatment
Himmerich, H., Zimmermann, P., Ising, M., Kloiber, S. M., Lucae, S., Kunzel, H. E., Binder, E. B., Holsboer, F., & Uhr, M. (2007) · Neuropsychobiology · doi:10.1159/000103573 · Cited by 46
Investigations into the involvement of leptin in responses to stress
Haleem, D. J. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000050 · Cited by 39
Strumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 49
Tadic, A. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2262 · Cited by 35
Kloiber, S., Ripke, S., Kohli, M. A., Reppermund, S., Salyakina, D., Uher, R., McGuffin, P., Perlis, R. H., Hamilton, S. P., Pütz, B., et al. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.08.010 · Cited by 34
Ghrelin Plasma Levels during Psychopharmacological Treatment
Himmerich, H., Fulda, S., Künzel, H. E., Pfennig, A., Dzaja, A., Cummings, D. E., & Pollmächer, T. (2005) · Neuropsychobiology · doi:10.1159/000086171 · Cited by 33
Self-citationPersonalized Medicine Using Neuroimmunological Biomarkers in Depressive Disorders
Chi, S., & Lee, M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020114 · Cited by 33
Anti-Inflammatory Drugs in Psychiatry
Berthold-Losleben, M., Heitmann, S., & Himmerich, H. (2009) · Inflammation & Allergy-Drug Targets · doi:10.2174/187152809789352221 · Cited by 32
Leptin potentiates GABAergic synaptic transmission in the developing rodent hippocampus
Guimond, D., Diabira, D., Porcher, C., Bader, F., Ferrand, N., Zhu, M., Appleyard, S. M., Wayman, G. A., & Gaïarsa, J. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00235 · Cited by 33
Kunzel, H. E., Ising, M., Zobel, A. W., Nickel, T., Ackl, N., Sonntag, A., Holsboer, F., & Uhr, M. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.06.006 · Cited by 32
Voigt, R. M., Mickiewicz, A. L., & Napier, T. C. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.07.009 · Cited by 30
Ma, Y., Balasubramanian, R., Pagoto, S. L., Schneider, K. L., Hébert, J. R., Phillips, L. S., Goveas, J. S., Culver, A. L., Olendzki, B. C., Beck, J., et al. (2013) · American Journal of Public Health · doi:10.2105/ajph.2013.301394 · Cited by 29
Schilling, C., Gilles, M., Blum, W. F., Daseking, E., Colla, M., Weber-Hamann, B., Lederbogen, F., Krumm, B., Heuser, I., Wudy, S. A., et al. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31827cb179 · Cited by 29
Almishri, W., Shaheen, A. A., Sharkey, K. A., & Swain, M. G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00803 · Cited by 30
Guo, Y., Young, B. L., Hainley, S., Palmer, J. L., & Bruera, E. D. (2007) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2007.03.032 · Cited by 30
Wang, Y., Bai, Y., Chen, J., Lin, C., Lai, I., & Liou, Y. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1122 · Cited by 29
Denys, D. A. J. P., Fluitman, S. B. A. H. A., Kavelaars, A., Heijnen, C. J., & Westenberg, H. G. M. (2005) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.08.016 · Cited by 26
Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia
Eller, T., Aluoja, A., Maron, E., & Vasar, V. (2009) · Medicina · doi:10.3390/medicina45120124 · Cited by 25
Tizzano, J. P., Stribling, D. S., Pérez–Tilve, D., Strack, A. M., Frassetto, A., Chen, R. Z., Fong, T. M., Shearman, L. P., Krieter, P. A., Tschöp, M. H., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.133132 · Cited by 25
Schüle, C., Baghai, T. C., Eser, D., Hecht, S., Hermisson, I., Born, C., Häfner, S., Nothdurfter, C., & Rupprecht, R. (2007) · The World Journal of Biological Psychiatry · doi:10.1080/15622970601136203 · Cited by 27
Tulner, D. M., Smith, O. R. F., Schins, A., de Jonge, P., Quere, M., Delanghe, J. R., Crijns, H. J., den Boer, J. A., Korf, J., & Honig, A. (2011) · Neuropsychobiology · doi:10.1159/000321624 · Cited by 23
Reduced MIP-1β as a Trait Marker and Reduced IL-7 and IL-12 as State Markers of Anorexia Nervosa
Keeler, J. L., Patsalos, O., Chung, R., Schmidt, U. H., Breen, G. D., Treasure, J. L., Himmerich, H., & Dalton, B. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080814 · Cited by 27
Jia, L., Shang, Y., & Li, Y. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.4377 · Cited by 22
Jiang, S.-M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i22.2867 · Cited by 21
Fernandes, B. M., Scotti-Muzzi, E., & Soeiro‐de‐Souza, M. G. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03240-8 · Cited by 26
Safer, D. L., Darcy, A. M., & Lock, J. (2010) · International Journal of Eating Disorders · doi:10.1002/eat.20793 · Cited by 20
Lee, H.-Y., Kang, R.-H., Paik, J., Jeong, Y. J., Chang, H. S., Han, S.-W., & Lee, M. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.013 · Cited by 19
Himmerich, H., Kaufmann, C., Schuld, A., & Pollmächer, T. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.04.012 · Cited by 22
Self-citationAlmeida, O. L. S., Ferriolli, E., Taveira, R. C. C., Rosenburg, M. G., Campanari, D. D., Alves, N. M. D. C., Pfrimer, K., Rapatoni, L., Peria, F. M., & Lima, N. K. C. (2023) · Cancers · doi:10.3390/cancers15143588 · Cited by 18
Effect of Venlafaxine, Pramipexole, and Valsartan on Spermatogenesis in Male Rats
Saleem, U., Zubair, S., Riaz, A., Anwar, F., & Ahmad, B. (2020) · ACS Omega · doi:10.1021/acsomega.0c02587 · Cited by 19
Mirtazapine Reduces Adipocyte Hypertrophy and Increases Glucose Transporter Expression in Obese Mice
Wu, C., Hou, P., Mao, F. C., Su, Y.-C., Wu, C.-Y., Yang, W., Lin, C., Tsai, H.-P., Liao, H.-J., & Chang, G. (2020) · Animals · doi:10.3390/ani10081423 · Cited by 17
Modulation of triglyceride accumulation in adipocytes by psychopharmacological agents in vitro
Löffler, D., Landgraf, K., Körner, A., Kratzsch, J., Kirkby, K. C., & Himmerich, H. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.10.008 · Cited by 18
Ataoğlu, S., Ankaralı, H. Ç., Samancı, R., Özşahin, M., & Admıs, O. (2017) · Northern Clinics of Istanbul · doi:10.14744/nci.2017.31644 · Cited by 28
Understanding the pharmacogenetics of selective serotonin reuptake inhibitors
Fabbri, C., Minarini, A., Niitsu, T., & Serretti, A. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.928693 · Cited by 15
Effect of mirtazapine on metabolism and energy substrate partitioning in healthy men
Hennings, J. M., Heel, S., Lechner, K., Uhr, M., Dose, T., Schaaf, L., Holsboer, F., Lucae, S., Fulda, S., & Kloiber, S. M. (2019) · JCI Insight · doi:10.1172/jci.insight.123786 · Cited by 16
Toxicological Assessment of Venlafaxine: Acute and Subchronic Toxicity Study in Rats
Paulis, M. G., Hafez, E. M., El‐Tahawy, N. F. G., & Aly, M. K. M. (2018) · International Journal of Toxicology · doi:10.1177/1091581818777470 · Cited by 16
Kubera, M., Roman, A., Basta‐Kaim, A., Budziszewska, B., Zajícová, A., Holáň, V., Rogóż, Z., Skuza, G., Leśkiewicz, M., Regulska, M., et al. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.11.017 · Cited by 13
Melatonin Prevents the Harmful Effects of Obesity on the Brain, Including at the Behavioral Level
Rubio‐González, A., Bermejo-Millo, J. C., de Luxán‐Delgado, B., Potes, Y., Pérez-Martínez, Z., Boga, J. A., Vega‐Naredo, I., Caballero, B., Solano, J. J., & Coto‐Montes, A. M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0796-8 · Cited by 18
Molecular Biomarkers for Pediatric Depressive Disorders: A Narrative Review
Lee, J., Chi, S., & Lee, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810051 · Cited by 13
Zeugmann, S., Quante, A., Popova-Zeugmann, L., Kössler, W., Heuser, I., & Anghelescu, I. G. (2012) · PubMed · Cited by 17
Monoaminergic‐based Pharmacotherapy for Depression
Papakostas, G. I., & Fava, M. (2005) · Wiley eBooks · doi:10.1002/9783527619672.ch6 · Cited by 11
Singh, M. P., & Singh, K. P. (2013) · National Academy Science Letters · doi:10.1007/s40009-012-0110-2 · Cited by 10
Nutritional Approach to Metabolic Changes Arising Out of Schizophrenia Therapy: Case Report
Özenoğlu, A., Uğurlu, S., Balcı, H., & Eker, E. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6323 · Cited by 10
Managing comorbid obesity and depression through clinical pharmacotherapies
McElroy, S. L., Guerdjikova, A. I., Mori, N. N., & Keck, P. E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1198776 · Cited by 11
Effect of acute and long-term exercise on leptin levels in depressed outpatients
Heinen, D., Heißel, A., Heinzel, S., Fydrich, T., Ströhle, A., Rapp, M. A., & Vogel, H. (2023) · BMC Public Health · doi:10.1186/s12889-023-17362-4 · Cited by 9
Metadata
- Authors
- Kraus, T., Haack, M., Schuld, A., Hinze-Selch, D., Koethe, D., & Pollmächer, T.
- Affiliations
- Max Planck Society (DE)
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2002-11
- Volume
- 35
- Issue
- 6
- Pages
- 220-225
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2002470967
- Cited by
- 144
- References
- 0
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 11 · 2013: 10 · 2012: 8
- FWCI
- 2.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- Max Planck Institute for Plasma Physics (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- mirtazapine, venlafaxine, antidepressant-induced weight gain, major depressive disorder, leptin, TNF-α, soluble TNF receptors, body weight, body mass index, psychotropic medication side effects
- MeSH terms
- Venlafaxine Hydrochloride, Mirtazapine, Adult, Aged, Body Weight, Cyclohexanols, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Longitudinal Studies, Male, Mianserin, Middle Aged, Antipsychotic Agents, Tumor Necrosis Factor-alpha, Body Mass Index, Cross-Over Studies, Leptin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.